Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Viridian Therapeutics, Inc., Halozyme Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Latest Biotechnology and Viridian Therapeutics, Inc., Halozyme Therapeutics, Inc. Stock News

As of December 2, 2025, Viridian Therapeutics, Inc. had a $2.9 billion market capitalization, compared to the Biotechnology median of $200.6 million. Viridian Therapeutics, Inc.’s stock is up 60.2% in 2025, down 2.2% in the previous five trading days and up 43.54% in the past year.

Currently, Viridian Therapeutics, Inc. does not have a price-earnings ratio. Viridian Therapeutics, Inc.’s trailing 12-month revenue is $70.8 million with a -426.6% net profit margin. As of December 2, 2025, Viridian Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-3.532 per share for the current fiscal year. Viridian Therapeutics, Inc. does not currently pay a dividend.

As of December 2, 2025, Halozyme Therapeutics, Inc. had a $7.8 billion market cap, putting it in the 76th percentile of all stocks. Halozyme Therapeutics, Inc.’s stock is up 39.5% in 2025, down 8.4% in the previous five trading days and up 42.5% in the past year.

Currently, Halozyme Therapeutics, Inc.’s price-earnings ratio is 14.4. Halozyme Therapeutics, Inc.’s trailing 12-month revenue is $1.2 billion with a 47.9% net profit margin. Year-over-year quarterly sales growth most recently was 22.1%. Analysts expect adjusted earnings to reach $6.138 per share for the current fiscal year. Halozyme Therapeutics, Inc. does not currently pay a dividend.

How We Compare Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Viridian Therapeutics, Inc.	VRDN	F
Halozyme Therapeutics, Inc.	HALO	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Viridian Therapeutics, Inc. has a Value Score of 2, which is Ultra Expensive. Halozyme Therapeutics, Inc. has a Value Score of 47, which is Average.

The Value Stock Winner: No Clear Winner

Neither Viridian Therapeutics, Inc., Halozyme Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Viridian Therapeutics, Inc., Halozyme Therapeutics or Inc. is the better investment when it comes to value.

Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Viridian Therapeutics, Inc.	VRDN	A
Halozyme Therapeutics, Inc.	HALO	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Viridian Therapeutics, Inc. has a Momentum Score of 91, which is Very Strong. Halozyme Therapeutics, Inc. has a Momentum Score of 69, which is Strong.

The Momentum Grade Winner: Viridian Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Viridian Therapeutics, Inc. is considered to have stronger momentum compared to Halozyme Therapeutics, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Viridian Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Viridian Therapeutics, Inc.	VRDN	B
Halozyme Therapeutics, Inc.	HALO	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Viridian Therapeutics, Inc. has a Earnings Estimate Score of 64, which is Positive. Halozyme Therapeutics, Inc. has a Earnings Estimate Score of 68, which is Positive.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc. have a grade of B. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether Viridian Therapeutics, Inc., Halozyme Therapeutics or Inc. is a better fit.

Other Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc. Grades

In addition to Momentum, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Viridian Therapeutics, Inc., Halozyme Therapeutics or Inc. Stock?

Overall, Viridian Therapeutics, Inc. stock has a Value Score of 2, Momentum Score of 91 and Estimate Revisions Score of 64.

Halozyme Therapeutics, Inc. stock has a Value Score of 47, Momentum Score of 69 and Estimate Revisions Score of 68.

Comparing Viridian Therapeutics, Inc., Halozyme Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.